Tin tức & Cập nhật
Xem bài viết Bệnh nhiễm khuẩn
Xem

Does molnupiravir improve outcomes in vaccinated COVID-19 patients?
The addition of molnupiravir to usual care does not reduce hospitalization or death in vaccinated, community-dwelling individuals at high risk of serious outcomes of COVID-19, results of the UK-based PANORAMIC trial showed. However, it may provide other benefits such as reducing time to recovery.

COVID-19 vaccines partially effective against Omicron BA.2 infection in children and adolescents in HK
According to a retrospective, territory-wide, case-based study, the mRNA-based BNT162b2 vaccine and inactivated CZ02 vaccine were partially effective against SARS-CoV-2 infection in children and adolescents during the Omicron BA.2 wave in Hong Kong.

BNT162b2 vax prevents delta, omicron infection in adolescents; benefits upped with booster dose
Full vaccination with the SARS-CoV-2 BNT162b2 vaccine reduced infection and hospitalization due to the delta and omicron variants of the SARS-CoV-2 infection, with an added benefit against the omicron variant in individuals who received a booster dose, according to a national study of Singaporean adolescents.

SAVE-MORE subgroup analysis further reinforces anakinra benefit in COVID-19
The benefit of anakinra treatment in patients hospitalized with COVID-19 is consistent regardless of age, sex, comorbidities, and suPAR* levels, according to subgroup analysis of the SAVE-MORE trial.





